ATLANTA, June 20 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. , a clinical stage biopharmaceutical company dedicated to the development of new and innovative gene therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease, today announced that Richard E. Otto, president and CEO, will be presenting at the upcoming Jefferies Life Science Conference at the Mandarin Oriental Hotel in New York on Tuesday, June 27, 2006 at 12:45 p.m. EDT.
Mr. Otto will discuss Corautus' technology platform, review additional clinical development activities and the Company's overall business strategy. The presentation will be accessible by webcast from the Investor Relations section of Corautus' website or by accessing the following link: http://www.wsw.com/webcast/jeff11/caq/.
Richard Otto stated, "We are very pleased to be included as a presenter at the Jefferies Life Sciences Conference and look forward to providing an update on our activities and plans for the future."
About Corautus Genetics
Corautus Genetics is a clinical-stage biopharmaceutical company dedicated to the development of gene transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease. Corautus is developing and testing a gene therapy product candidate using the VEGF-2 gene to promote therapeutic angiogenesis in ischemic muscle. Corautus has a strategic alliance with Boston Scientific Corporation to develop, commercialize and distribute the VEGF-2 gene therapy products. For more information, please visit www.corautus.com.
CONTACTS: Corautus Genetics Inc. Michael K. Steele (404) 526-6212 msteele@corautus.com
Corautus Genetics Inc.CONTACT: Michael K. Steele of Corautus Genetics Inc., +1-404-526-6212, ormsteele@corautus.com
